Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I Open-Label, Dose Escalation Study of the Safety and Tolerability of Tolododekin Alfa (ANK-101) in Advanced Solid Tumors

Next Previous
Trial Profile

A Phase I Open-Label, Dose Escalation Study of the Safety and Tolerability of Tolododekin Alfa (ANK-101) in Advanced Solid Tumors

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 28 Nov 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Tolododekin alfa (Primary)
  • Indications Adenocarcinoma; Advanced breast cancer; Bladder cancer; Head and neck cancer; Lung cancer; Male breast cancer; Malignant melanoma; Solid tumours; Squamous cell cancer
  • Focus Adverse reactions; First in man
  • Acronyms ANCHOR
  • Sponsors Ankyra Therapeutics

Most Recent Events

  • 04 Nov 2025 According to an Ankyra Therapeutics media release, company will be presenting initial data with their ANK-201 at the Society for Immunotherapy of Cancer annual meeting on November 7, 2025.
  • 04 Nov 2025 According to an Ankyra Therapeutics media release, company recently completed dose escalation in this study.
  • 04 Nov 2025 According to an Ankyra Therapeutics media release, company announced the publication online of Part 1 results from its Phase 1 first-in-human study of tolododekin alfa in Nature Communications in the September 29, 2025, issue.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top